Skip to main content

Revolutionize the treatment paradigm for Diabetic Retinopathy

R&D program with distinct and novel drug candidates with relevant modes-of-action in the diabetic retinopathy pathophysiology.

Diabetic Retinopathy

Novaliq Transforms Ophthalmic Topical Therapies

Our unique and versatile water-free technology revolutionizes ocular therapies.

EyeSol^® is a novel drug category of drugs

Our products are beneficial for the ocular surface, micro-dosed and non-preserved targeting multiple ophthalmic diseases with a “smart” eye drop.

Overcoming Limitations in Eye Care Therapies

Our technology, opens completely new and exciting opportunities in the eye care for the relief and prevention of ophthalmological diseases in various indications for patients.

We revolutionize dry eye drug therapies

Two new and distinct drug products approved in Dry Eye Disease by the US FDA in 2023.

Dry Eye Disease

Technology

EyeSol^® is a novel drug category of water-free therapies

Our technology

Disease Areas & Pipeline

Novaliq offers an industry-leading portfolio of topical drug products that are water-free.

See More

Diabetic Retinopathy Program

Blepharitis

Dry Eye Disease

Uveitis

Clinical Development Projects

Clinical Development Projects

NOV05

A steroid-free treatment option for Non-Infectious Anterior Uveitis.

BOT-3

a first-in-class, on-label treatment for blepharitis

News & Media

Reach more about our latest press releases, key scientific
publications and other company resources

Latest Publication

Corneal Staining Responder Analysis A Clinically Meaningful Dry Eye Outcome

Latest Press Release

Hengrui’s Heng Yi^® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Novaliq is a private biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol^®, the worldwide first water-free ophthalmic technology.

About us